Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne A Ray

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
BMJ (Clinical Research Ed.)|January 13, 2011
Cardiovascular safety of NSAIDsWayne A Ray
The New England Journal of Medicine|December 2, 2005
Observational studies of drugs and mortalityWayne A Ray
The New England Journal of Medicine|February 22, 2008
Learning from aprotinin--mandatory trials of comparative efficacy and safety neededWayne A Ray
American Journal of Epidemiology|October 31, 2003
Evaluating medication effects outside of clinical trials: new-user designsWayne A Ray
Evidence-Based Medicine|August 15, 2014
Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertainWayne A Ray
The New England Journal of Medicine|October 24, 2003
Population-based studies of adverse drug effectsWayne A Ray
Epidemiology (Cambridge, Mass.)|April 6, 2011
Improving automated database studiesWayne A Ray
American Journal of Epidemiology|July 14, 2011
Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confoundersPatrick G Arbogast, Wayne A Ray
JAMA|April 5, 2022
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-ReplyWayne A Ray, Katherine T Murray
The New England Journal of Medicine|May 16, 2008
The aprotinin story--is BART the final chapter?Wayne A Ray, C Michael Stein
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
BMJ (Clinical Research Ed.)|January 13, 2011
Cardiovascular safety of NSAIDsWayne A Ray
The New England Journal of Medicine|December 2, 2005
Observational studies of drugs and mortalityWayne A Ray
The New England Journal of Medicine|February 22, 2008
Learning from aprotinin--mandatory trials of comparative efficacy and safety neededWayne A Ray
American Journal of Epidemiology|October 31, 2003
Evaluating medication effects outside of clinical trials: new-user designsWayne A Ray
Evidence-Based Medicine|August 15, 2014
Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertainWayne A Ray
The New England Journal of Medicine|October 24, 2003
Population-based studies of adverse drug effectsWayne A Ray
Epidemiology (Cambridge, Mass.)|April 6, 2011
Improving automated database studiesWayne A Ray
American Journal of Epidemiology|July 14, 2011
Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confoundersPatrick G Arbogast, Wayne A Ray
JAMA|April 5, 2022
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-ReplyWayne A Ray, Katherine T Murray
The New England Journal of Medicine|May 16, 2008
The aprotinin story--is BART the final chapter?Wayne A Ray, C Michael Stein
Pageof 10